Köse, Ozlem <br/><br/>
New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.  [electronic resource] 

 -  Seminars in thrombosis and hemostasis  Sep 2010 
 - 669-72 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1098-9064 
<br/><br/><label>Standard No.: </label>10.1055/s-0030-1262889  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--immunology<br/>Antibodies, Monoclonal, Humanized<br/>Complement C3b Inactivator Proteins--genetics<br/>Complement C5--immunology<br/>Complement Factor H--genetics<br/>Complement Pathway, Alternative--drug effects<br/>Female<br/>Gene Deletion<br/>Hemolytic-Uremic Syndrome--drug therapy<br/>Humans<br/>Mutation<br/>Polymorphism, Genetic<br/>Treatment Outcome<br/>Young Adult